carboplatin + irinotecan hydrochloride
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Unspecified Childhood Solid Tumor, Protocol Specific
Conditions
Unspecified Childhood Solid Tumor, Protocol Specific
Trial Timeline
Jun 1, 2001 → Dec 1, 2003
NCT ID
NCT00024284About carboplatin + irinotecan hydrochloride
carboplatin + irinotecan hydrochloride is a phase 1 stage product being developed by Bristol Myers Squibb for Unspecified Childhood Solid Tumor, Protocol Specific. The current trial status is completed. This product is registered under clinical trial identifier NCT00024284. Target conditions include Unspecified Childhood Solid Tumor, Protocol Specific.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00024284 | Phase 1 | Completed |
Competing Products
20 competing products in Unspecified Childhood Solid Tumor, Protocol Specific
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DJ-927 + capecitabine | Daiichi Sankyo | Phase 1 | 33 |
| E7389 + E7389 + E7389 | Eisai | Phase 1 | 33 |
| bevacizumab + enzastaurin hydrochloride | Eli Lilly | Phase 1 | 33 |
| SHR-1916 | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| PI3K inhibitor BKM120 + docetaxel | Novartis | Phase 1 | 33 |
| bevacizumab + cyclophosphamide + imatinib | Novartis | Phase 1 | 33 |
| capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev) | Novartis | Phase 1 | 33 |
| warfarin | Novartis | Phase 1 | 33 |
| RLY-1971 | Roche | Phase 1 | 33 |
| Domvanalimab + Zimberelimab | Gilead Sciences | Phase 1 | 32 |
| BEZ235 + MEK162 | Pfizer | Phase 1 | 32 |
| Utomilumab + ISA101b | Pfizer | Phase 2 | 51 |
| Irinotecan | Pfizer | Phase 1 | 32 |
| Ixabepilone + Sunitinib | Pfizer | Phase 1 | 32 |
| ixabepilone + lapatinib ditosylate | Bristol Myers Squibb | Phase 1 | 32 |
| intoplicine | Sanofi | Phase 1 | 32 |
| apomine | Sanofi | Phase 1 | 32 |
| apomine | Sanofi | Phase 1 | 32 |
| Sorafenib | Bayer | Phase 2 | 49 |